ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07726
-0,14%
Bitcoin
61.420,86
1,02%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Europa
  5. EU
  6. Pharming Group NV (PHARM)

  7. Pharming Group NV (PHARM) News

PHARM

Pharming Group NV (PHARM)

Pharming Group NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:PHARM
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202407h00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
08/05/202407h00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
24/04/202408h00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202407h00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
24/04/202407h00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202418h43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202415h04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202408h00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202407h00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
08/04/202407h00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202408h30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202407h00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202408h00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
03/04/202408h00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202407h00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202408h00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
29/02/202408h00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202408h00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/02/202408h00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202407h00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
08/01/202407h00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202307h00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
21/11/202307h00GlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
21/11/202307h00GlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
10/11/202314h51GlobeNewswire Inc.Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalEU:PHARMPharming Group NV
01/11/202308h00GlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
01/11/202308h00GlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
26/10/202307h00GlobeNewswire Inc.Pharming Group reports third quarter 2023 financial resultsEU:PHARMPharming Group NV
12/10/202308h00GlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
12/10/202308h00GlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
 Showing the most relevant articles for your search:EU:PHARM

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
CCOM
SILVER
SILVER
FX
EURUSD
Euro vs US Dollar
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AAPL
Apple
COIN
SOLUSD
Solana
NYSE
MCD
McDonalds
FX
EURGBP
Euro vs Sterling
DBI
DAX
DAX
DBI
MDAX
MDAX
NYSE
NKE
Nike
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten